FDA clears Ziopharm Oral Palifosfamide IND
Palifosfamide (Zymafos or ZIO-201) is a novel DNA cross-linker that in preclinical study has shown to bypass resistance mediated by aldehyde dehydrogenase (ALDH), in addition to conferring a
The US Food and Drug Administration (FDA) has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).